Helix BioPharma Corp. announced voting results from its Annual General and Special Meeting held on January 30, 2026, with shareholders demonstrating near-unanimous support for all proposed resolutions. A total of 61,885,815 common shares were voted at the meeting, representing 81.03% of the company's total issued and outstanding shares. All four director nominees listed in the company's Management Information Circular dated December 15, 2025, were re-elected with approximately 99.99% of votes cast in favor. The re-elected directors are Jacek Antas, Jerzy Leszczynski, Janusz Grabski, and Malgorzata Laube. Shareholders also approved the appointment of Clearhouse LLP as auditor until the next annual general meeting, with remuneration to be determined by the directors, receiving 99.99% support.
A significant resolution approved with 99.99% of votes in favor authorizes an amendment to the company's articles to effect a consolidation of issued and outstanding common shares. The consolidation ratio could be up to five pre-consolidation shares for one post-consolidation share, with the board authorized to determine the final ratio at its discretion. The shareholder approval of the share consolidation proposal provides the board with flexibility to potentially adjust the company's capital structure. Such consolidations are often pursued to meet stock exchange listing requirements or improve perceived market valuation. A report on all items of business voted at the meeting will be filed on SEDAR+ at https://www.sedarplus.com.
Helix BioPharma is a clinical-stage oncology company focused on developing novel therapies for hard-to-treat cancers. The company's pipeline includes a proprietary technology platform of bio-conjugates targeting CEACAM6-expressing solid tumors. Its lead candidate, L-DOS47, has completed Phase Ib studies in non-small cell lung cancer and represents an antibody-enzyme conjugate designed to neutralize the tumor microenvironment. The overwhelming support for all resolutions indicates strong shareholder confidence in the current leadership and strategic direction as Helix continues its clinical development programs in oncology. The company's forward-looking statements and detailed risk factors are available in its annual management's discussion and analysis and Annual Information Form filed on SEDAR+. Additional information about the company can be found at https://www.helixbiopharma.com.
